Given both the rarity and the aggressiveness of this breast cancer subtype, more research incorporating larger datasets needs to be conducted, in order for HDAC-2 to be defined as a novel trustworthy index of aggressiveness, as well as a target in the context of triple negative breast cancer treatment. This evidence concerns the gene HDAC2 and triple-negative breast carcinoma.